PR for 24 wks (Arm 2). A total 244 genotype check details 1, non-cirrhotic, treatment-naïve subjects with IL28B CC genotype were randomized 1:1 and dosed. Subjects in Arm 1 with HCV RNA

predictors of relapse in the 6 wk treatment group. There was no difference in GT 1a and 1b responses. Treatment-related adverse events were rare and primarily consistent with PR treatment. The mean change in Hgb, WBC and platelets was similar between Arm 1 and Arm 2. Total bilirubin elevations during wks 1–4 of treatment were observed more

frequently in Arm 1. Fewer study treatment dose modifications or discontinuations for safety were seen in the 6 wk treatment group. Conclusions: These data demonstrate a high SVR12 (82–100%) with 6 or 12 wks of two direct-acting antivirals plus PR result in high rates of response in a treatment naïve, non-cirrhotic, Small molecule library concentration IL28 CC population. Additionally, 12 wks of the 4 drug regimen is comparable to 24 wks of PR. W RAHMAN,1 T TU,4 M BUDZINSKA,4 P HUANG,2,3 L BELOV,2,3 JS CHRISP,2 RI CHRISTOPHERSON,3 FJ WARNER,4 J GEORGE,5 DG BOWEN,1,4 SI STRASSER,1 D KOOREY,1 AF SHARLAND,6 GW MCCAUGHAN,1,4 JYH YANG,7 NA SHACKEL1,4 1A.W. Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Camperdown, NSW, Australia, 2Medsaic Pty Ltd, Suite 145, Level 1, National Innovation Centre, Australian Technology Park, Garden Street, Eveleigh, Australia, 3School of Molecular and Microbial Biosciences, The University of Sydney, NSW, Australia, 4Centenary selleck screening library Institute, Sydney, NSW Australia, 5Storr Liver Unit, Westmead Millennium Institute, University of Sydney, Australia, 6Collaborative Transplantation Research Group, Bosch Institute, The University of Sydney, 7School of Mathematics and Statistics, The University of Sydney, NSW,

Australia Background: Hepatitis C virus (HCV)-related end-stage liver disease is a primary indication for liver transplantation. At present, severe HCV recurrence is poorly determined by liver biopsies and viral load. Non-invasive means of predicting severe recurrence are required. CD antibody microarrays, which use a live cell-capture technique, enable a semi-quantitative leucocyte immunophenotype. We have previously used this assay to demonstrate disease specific consensus patterns of expression of CD antigens for patients with chronic liver disease including hepatitis C virus (HCV) infection. Aims: To determine CD antigen expression profiles for patients undergoing liver transplantation for active HCV infection looking for preserved disease-specific signatures predictive of outcomes.